Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tigran Makunts, Ruben Abagyan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-06-01
coleção:	Frontiers in Psychiatry
Assuntos:	DILI (drug-induced liver injury) MDMA DDI (drug-drug interaction) FAERS adverse events MDMA (3,4-methylenedioxymethamphetamine)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1414622/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!